Infliximab and methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of dosage regimens

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 1939-1955

  Zintzaras, Elias ^a,b   Dahabreh, Issa J ^c   Giannouli, Stavroula ^c   Voulgarelis, Michael ^c   Moutsopoulos, Haralampos M ^c  

^a UNIVERSITY OF THESSALY   (Greece)

^b Institute for Clinical Research and Health Policy Studies   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

efficacy; infliximab; meta analysis; methotrexate; rheumatoid arthritis; tolerability

Indexed keywords

INFLIXIMAB; METHOTREXATE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 57749180869     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.11.007     Document Type: Article

References (51)

1. Scott D.L., Pugner K., Kaarela K., et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39 (2000) 122-132
2. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
3. Charles P., Elliott M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163 (1999) 1521-1528
4. Quinn M.A., Conaghan P.G., and Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence?. Rheumatology (Oxford) 40 (2001) 1211-1220
5. Lipsky P.E., van der Heijde D.M., St. Clair E.W., et al., for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
6. Newsome G., and for the American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 Update. J Am Acad Nurse Pract 14 (2002) 432-437
7. Maetzel A., Wong A., Strand V., et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-ruematic drugs. Rheumatology (Oxford) 33 (2000) 975-981
8. Harriman G., Harper L.K., and Schaible T.F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alpha treatment. Ann Rheum Dis 58 Suppl 1 (1999) 161-164
9. Hochberg M.C., Tracy J.K., Hawkins-Holt M., and Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62 Suppl 2 (2003) ii13-ii16
10. Donahue K.E., Gartlehner G., Jonas D.E., et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148 (2008) 124-134
11. Kavanaugh A., St. Clair E.W., McCune W.J., et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27 (2000) 841-850
12. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
13. Maini R., St. Clair E.W., Breedveld F., et al., for the ATRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotraxate: A randomized phase III trial. Lancet 354 (1999) 1932-1939
14. Elliott M.J., Maini R.N., Feldmann M., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arth hrit tis Rheum 36 (1993) 1681-1690
15. Elliott M.J., Maini R.N., Feldmann M., et al. Random mised double e-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 34 (1994) 1105-1110
16. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for th he classific cation of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
17. Felson D.T., Anderson J.J., Boers M., et al., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
18. Whitehead A. Meta-Analysis of Controlled Clinical Trials (2002), John Wiley & Sons, Chichester, UK
19. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997) 820-826
20. Zintzaras E., and Ioannidis J.P. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 21 (2005) 3672-3673
21. Zintzaras E., and Ioannidis J.P. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28 (2005) 123-137
22. Altman D.G., and Bland J.M. Interaction revisited d: The difference between two estimates. BMJ 326 (2003) 219
23. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165 (2005) 2337-2344
24. Zintzaras E., Stefanidis I., Santos M., and Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic monoclonal antibody (cA2). Arthritis Rheum 41 (1998) 2205-2210
25. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
26. Breedveld F.C., Han C., Bala M., et al. Association between baseline radiograhic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 64 (2005) 52-55
27. Breedveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 (2004) 149-155
28. Smolen J.S., Han C., Bala M., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tummor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52 (2005) 1020-1030
29. St. Clair E.W., van der Heijde D.M., Smolen J.S., et al., for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
30. Abe T., Takeuchi T., Miyasaka N., et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33 (2006) 37-44
31. Perkins D.J., St. Clair E.W., Misukonis M.A., and Weinberg J.B. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha trexate: A randomised phase III trial. Lancet 354 (1999) 1932-1939
32. Westhovens R., Yocum D., Han J., et al., for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. [published correction appears in Arthritis Rheum. 2007;556:11675]. Arthritis Rheum 54 (2006) 1075-1086
33. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study): A randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
34. Taylor P.C., Steuer A., Gruber J., et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50 (2004) 1107-1116
35. Antoni C., and Kalden J.R. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 17 Suppl 18 (1999) S73-S77
36. Durez P., Nzeusseu Toukap A., Lauwerys B.R., et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 63 (2004) 1069-1074
37. Quinn M.A., Conaghan P.G., O'Connor P.J., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month ran-liver disease?. Hepatology 43 (2006) 352-361
38. Sidiropoulos P., Bertsias G., Kritikos H.D., et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: Dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63 (2004) 144-148
39. Harley C.R., Frytak J.R., and Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 99 Suppl 6 (2003) S136-S143
40. Durez P., Van den Bosch F., Corluy L., et al. A dose adjustment in patients with rheum mato oid arth hrit tis not optimally responding to a standard dose of infliximab of 3 mg/kkg every 8 weeks can be effective: A Belgian prospectiv ve study. Rheumatology (Oxford) 44 (2005) 465-468
41. van Vollenhoven R.F., Brannemark S., and Klareskog L. Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-llike effect. Ann Rheum Dis 63 (2004) 426-430
42. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and metaanalysis of rare harmful effects in randomized controlled trials. [published correction appears in JAMA. 2006;2295:2482]. JAMA 295 (2006) 2275-2285
43. Edwards C.J., Arden N.K., Fisher D., et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (OOxford) 44 (2005) 1394-1398
44. Grijalva C.G., Chung C.P., Stein C.M., et al. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford) 47 (2008) 1061-1064
45. Balk E.M., Bonis P.A., Moskowitz H., et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 287 (2002) 2973-2982
46. Thompson S.G. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309 (1994) 1351-1355
47. Jüni P., Witschi A., Bloch R., and Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (1999) 1054-1060
48. Gleser L.J., and Olkin I. Stochastically dependent effect sizes. In: Cooper H., and Hedges L.V. (Eds). The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York, NY 339-355
49. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology 1 (1990) 43-46
50. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
51. Lau J., Ioannidis J.P., Terrin N., et al. The case of the misleading funnel plot. BMJ 333 (2006) 597-600